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Background: Adenosine deaminase (ADA) is an enzyme that plays important roles in proliferation, maturation,
function and development of the immune system. ADA activity may be altered by variety of substances including
synthetic or natural products. Morphine, cocaine and their analogs exert immune suppressive activities by
decreasing immune system function. The purpose of this study is to confirm that this possible effect may be
modulated by interaction of these substances with ADA activity by experimental and computational method.
Methods: The structural changes in ADA have been studied in presence of cocaine, ethylmorphine, homatropine,
morphine and thebaine by determination of ADA hydrolytic activity, circular dichroism and fluorescence
spectroscopy in different concentrations. Docking study was performed to evaluate interaction method of test
compound with ADA active site using AutoDock4 software.
Results: According to in-vitro studies all compounds inhibited ADA with different potencies, however thebaine
activated it at concentration below 50 μM, ethylmorphine inhibited ADA at 35 μM. Moreover, fluorescence spectra
patterns were differed from compounds based on structural resemblance which were very considerable for cocaine
and homatropine.
Conclusion: The results of this study confirms that opioids and some other stimulant drugs such as cocaine can
alter immune function in illegal drug abusers. These findings may lead other investigators to develop a new class of
ADA activators or inhibitors in the near future.
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Adenosine deaminase (ADA) is an enzyme that irrevers-
ibly converts adenosine to inosine [1]. This enzyme ex-
ists in all human tissues, but the highest levels and
activity are found in the lymphoid system such as lymph
nodes, spleen, and thymus [2]. It is also essential for the
proliferation, maturation and function of T lymphocyte
cells. It is assumed that ADA plays a crucial role in de-
velopment of the immune system, while its innate defi-
ciency causes severe combined immunodeficiency (SCID)
[3]. Moreover, ADA activity changes in a variety of other
diseases including acquired immunodeficiency syndrome* Correspondence: amanlou@tums.ac.ir
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unless otherwise stated.(AIDS), anemia, various lymphomas, tuberculosis, and
leukemia [4,5]. On the other hand, ADA regulates the
levels of endogenous adenosine which results in immune
system suppression by inhibiting lymphoid or myeloid
cells [6,7], including neutrophils [8], macrophages [9],
lymphocytes [10,11] and platelets [12].
Two distinct isoenzymes of ADA, known as ADA1 and
ADA2, are found in mammalian [13-15]; former has
highest levels of activity in spleen, and thymus whereas
latter is found in other parts of body [15]. As the most
abundant type of white blood cells that responds to infec-
tion and attacks of foreign invaders, neutrophils might
possess more than one type of adenosine receptor [16],
and adenosine regulates neutrophil function in an oppos-
ing manner through the ligation of ADA1 (immunostimu-
latory) and ADA2 (immunosuppressive) receptors [17].al Ltd. This is an Open Access article distributed under the terms of the Creative
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potency have been reported [18]. In one study, immuno-
suppressive and anti-inflammatory effects of FR234938,
as a non-nucleoside inhibitor of ADA, were investigated
[19]. Moreover, deoxycoformycin, another ADA inhibitor,
has been investigated in treatment of colon carcinoma
cells [20,21] and hematological neoplasms [22]. By con-
trast, ibuprofen [23] and medazepam [24] effects on im-
mune deficiency have been reported. This revealed that
purine compound may act as ADA activator; but still
more experiments are needed to confirm this finding.
Opioids have variety of clinical applications. Naltrex-
one in low dosage can suppress human ovarian cancer
and provides novel non-toxic therapies for the treatment
of this lethal neoplasia [25]. The idea that opioids sup-
press the immune system and reduce resistance to infec-
tions is not new [26]. Several studies on animals and
humans have illustrated that opioids can exert immuno-
suppressive effects by interfering B and T cell function
[27-29]. In this regard, Sacerdote et al. have reported
that immune function is affected by morphine and tram-
adol [30]. In other investigations, chronic treatment with
morphine has been shown to affect the function of T
cells and reduce immunity by directly interacting with
cells of the immune system [28,30-34]. On the other
hand, studies about heroin abusers showed that patients
were suffering from a disease that diminishes their im-
munity, by affecting T-lymphocyte function and there-
fore cause (HIV) infection [33,34]. In addition, long term
usage of cocaine and homatropine leads to a heart attack,
tremors, and apnea, cardiac arrest respectively. The possible
involvement of adenosine in opioid antinociception has
been supported by Ho et al. [34]. Interaction between an
opioid and an adenosine receptor has been proposed. Yet,
binding efficiency of ADA1 is reduced in the presence of
morphine [35,36]. Also, transferring of opioids to the pon-
tine reticular formation (PRF) and substantia innominata
(SI) causes adenosine to decrease in the PRF and SI [37].
Although the knowledge about effects of opioids on
immune responses has been improved, there is rela-
tively little information about these immunosuppres-
sive effects. Therefore, the present investigation was
conducted to find the effects of this group of opiates and
two other alkaloid compounds on ADA activity; by means
of computational and experimental methods to found




Adenosine deaminase (EC 3.5.4.4) extracted from bovine
spleen was purchased from sigma, and all other used
materials were of analytical grade and acquired from
Merck. PBS that is used in assay was adjusted at 7.4, atwhich, enzyme has optimal activity in [38,39]. All solu-
tions were prepared in MilliQ (Millipore, USA) water.
Biological assays
Released ammonia resulted by enzyme activity was deter-
mined by specific Berthelot colorimetric method which
was used for micro determination of ADA activity in
serum [40]. Briefly, this method is based on the reaction
of liberated ammonia with hypochlorite (OCl−) to form a
monochloramine and subsequent reaction of this inter-
mediate with phenol to produce blue-colored indophenols
that absorbance is measured at 625 nm. In this process so-
dium nitroprusside is used as the catalyst. The reaction
was initiated by addition of adenosine as a substrate at
37°C to preincubated enzyme with different concentra-
tions of tested compounds at different concentrations
(5–300 μM). Finally, the enzymatic reaction was stopped
at the end of 30 minutes of incubation by adding phenol
nitroprusside solution. The mixture kept again for 30 mi-
nutes at 37°C before absorbance determination.
Obtained absorbance was normalized through blank
sample, and IC50 values were calculated by Prism soft-
ware (Ver. 5, GraphPad Software Inc., San Diego CA,).
Circular dichroism spectroscopy
CD spectra were measured in the far-UV (200–260 nm)
region with JASCO J-715 spectropolarimeter (Japan).
JASCO J-715 software not only gave us the possibility of
data smoothing, but also used to predict the secondary
structure changes of the protein according to the statis-
tical method [41]. Each scan was recorded in 1 nm in-
crements at 37°C, repeated three times, and averaged.
The protein was in 0.1 M PBS buffer, pH = 7.4, and its
concentration was adjusted to 2 mg/ml in 1 cm path
length cuvette. The results were expressed in molar el-
lipticity [θ] (deg cm2.dmol−1).
Fluorescence spectroscopy
Fluorescence spectroscopy was performed on a Hitachi
fluorescence spectrophotometer model MPF-4 with 1 cm
path length fluorescence cuvette and final volume of
400 μL. The excitation wavelength was adjusted in 290 nm,
and the emission was scanned every 1 nm in the range of
300 to 400 nm. The final concentration of enzyme was
6 μM and different concentrations of tested compounds
were changed from 1.7 to 73.4 μM.
Docking simulation
To have a better understanding about the inhibitory
mechanism of the test compounds and clarification of
type of interactions, docking were performed using the
AutoDock 4.2 package [42]. The ability of software in
next predictions was determined with re-docking of co-
crystallized inhibitor of protein x-ray structure pdb ID:
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structure. This crystal structure has been used since its >
80% similarity in structure with bovine spleen and active
site amino acids conservation. The structure of all com-
pound have sketched by Marvin sketch applet (Marvin
package, Chemaxon Company). AutoDockTools (ADT)
1.5.6 was used for preparing input files using Autodock







*Thebaine was activated ADA till this concentration.Adding polar hydrogens and rotatable bonds were done
with ADT; docking with a maximum number of 25 × 106
energy evaluations using the Lamarckian Genetic Algo-
rithm (LGA) were performed. All other parameters were
set to default values. The docked conformations of each
ligand were ranked into clusters based on the binding en-
ergy. After clustering analysis, conformation with the most
favourable binding energy was selected.in presence of 2 mg/ml adenosine deaminase enzyme







Figure 1 Ethylmorphine binding site of adenosine deaminase 2D (a) and 3D (b) demonstration.
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Determination of ADA activity
The target compounds were evaluated against ADA en-
zymatic activity in vitro and obtained IC50 values are
summarized in Table 1. As shown in Table 1 all tested
compounds inhibit ADA activity in micromolar range.
In general, compounds in group1 (consisted of ethyl-
morphine, morphine and thebaine) showed better in-
hibitory activities than compounds in the other structurally
related group (group 2: cocaine and homatropine). As
shown, despite of partially closed binding energies, each
compound inhibits the enzyme in variety of concentra-
tions. Enhance in inhibition potency may be due to a de-
crease in conformational flexibility and better stabilization
in inhibition site. In first group the order of inhibitory ac-
tivities showed the potency of ethylmorphine >morphine >
thebaine. This tendency is due to the presence of differ-
ent substitute on A and C rings of perhydrophenan-
threne structure. Ethylmorphine with ethoxy group on A
ring shows better potency (IC50: 35 μM) than those with
hydroxyl and methoxy substitutes. Upon further modifica-
tion on C-ring in thebaine, the activity further decreased.a) b)
Figure 2 Docking pose of cocaine and homatropine in the adenosine
conformation: a) Overlay of cocaine and homatropine. b) Cocaine andThis drop in inhibition activity may be due to inappropri-
ate stabilization of compound to bind to target amino
acids or inappropriate interactions which was confirmed
by the molecular docking study. The binding energy of
thebaine was calculated −7.2 kcal/mol compare to ethyl-
morphine (ΔG°: −8 kcal/mol). Interestingly in this series,
thebaine activated enzyme hydrolytic activity till 50 μM
and up to this level showed inhibition effect with IC50:
163 μM (Table 1). However, thebaine, cocaine and homa-
tropine shows IC50 higher than other inhibitors (ethyl-
morphine and morphine), it can imply some immunity
problem in the opioid consumers may result by ADA
inhibition.
In another group hydroxyl substitution may be respon-
sible for the homatropine inhibition efficiency which
might build H-bond with adjacent residues at active site
of ADA. In addition, cocaine showed weaker inhibitory
activity which indicated the influence of position and
size of the substitute on tropan ring on the inhibitory
activity. For more insight to obtained IC50 values and
interaction site recognition the docking study has been
performed.c)
deaminase binding pocket at their lowest energy of binding
c) Homatropine.
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Docking studies are used at different stages of drug dis-
covery such as in the prediction of ligand-receptor inter-
action and also to rank the compounds based on the
binding energies. Docking of co-crystallized inhibitor with
ADA was performed to evaluate the efficacy of docking
software and the reasonable RMSD of 0.39 Å was ob-
tained. Docking of tested compounds with the ADA en-
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e) Thebaine enzyme1.8  µM
11   µM
27.2µM
73.4µM
Figure 3 Change in fluorescence spectra of adenosine deaminase in p
Cocaine, c) Morphine, d) Ethylmorphine, and e) Thebaine in pH: 7.4.were determined as shown in Table 1. The interacting
energies followed the order of the in vitro IC50 values
with rational correlation (R2: 0.84). All compounds posed
in ADA active site entrance or partially penetrated in ac-
tive site.
For the most potent inhibitor, ethylmorphine, the hy-
droxyl group of C-ring formed a hydrogen bond with
Met155 and His157. Moreover, presence of ethoxy group



































































resence of different concentration of a), Homatropine, b)
Amanlou et al. DARU Journal of Pharmaceutical Sciences 2014, 22:42 Page 6 of 8
http://www.darujps.com/content/22/1/42Phe65, Leu106, Met155 and Ala183 as well as electrostatic
interaction of nitrogen atom made it much more stabi-
lized in binding site (Figure 1). Thebaine exhibited


















a) Homatropine 290 µM
230 µM
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Figure 4 CD spectra of adenosine deaminase in presence of differ
c) Morphine, d) Ethylmorphine, e) Thebaine in pH: 7.4.the experimentally observed activity due to flat T-shape
structure which resulted in less penetration into active
site. On the other hand, in comparison to morphine re-








































b) Cocaine 290 µM
230 µM
80   µM
0     µM
ent concentration (0–300 μM) of a) Homatropine, b) Cocaine,
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in lower efficiency. This effect was illustrated in ethylmor-
phine which in existing H-bond made it more stabilized in
binding site. In the other group, homatropine binds to
ADA with lower binding energy than cocaine with IC50 96
and 180 μM respectively. As it shown in Figure 2 cocaine
doesn’t diffuse into active site because of bulkier substi-
tute, and just poses on enzyme active site entrance. In
contrast, homatropine enters from phenyl part and OH
group makes H-bond with Leu62.
Fluorescence spectroscopy
Interaction of tested compounds with Trp residues can
be studied by change in emission spectra of ADA in
320-340 nm. In other words, any environmental alter-
ation as well as three-dimensional structure changes in
Trp amino acid and enzyme respectively, can change the
innate spectrum of Trp residues in enzyme. As shown in
Figure 3, there are two totally different patterns in inter-
action with Trp residues. In the first group, homatropine
and cocaine in high concentrations, demonstrate batho-
chromic shift. This change may be probably due to severe
change of three dimensional structure of the enzyme. In
the other series: morphine, ethylmorphine and thebaine
do not show noticeable change and shift in fluorescence
spectra; indeed compounds with bulkier structure don’t
penetrate efficiently in binding pocket, and place in longer
distance with Trp residues. Thebaine and ethylmorphine
in this group decrease Trp emission as their concentration
increase. This could be an indication that these com-
pounds have bonded with the active sites or other sites of
the ADA enzyme and therefore the Trp amino acid is out
of access. According to the Berthelot test results, thebaine
till 50 μM stimulates enzyme to break down faster, but
above this concentration the activity of thebaine slows
down and the concentration of 163 μM, results in 50% of
inhibition.
Circular dichroism spectroscopy
CD spectra of ADA in the presence of different concen-
tration of compounds have been illustrated in Figure 4.
ADA showed two transitions in 210 and 222 nm which
are attribute to n→ π* and π→ π* respectively. Accord-
ing to percent of different patterns of 2D structure of
enzyme, among α-helix structure has been undergone
sever changes, and mostly convert to random coil. This
effect can be explained by compounds intercalation be-
tween helix residues and broken of H-bonds. According
to the Figure 3 in high concentrations of cocaine, batho-
chromic shift in the fluorescence spectra was observed.
On the other hand as it shown in Figure 4, in cocaine
concentration around 180 μM drastic changes in CD
spectra were observed. Also, based on in-vitro studies
50% of enzyme’s activity has been diminished in 180 μM,so it can infer from this point despite of strong alteration
in overall ADA structure or active site remains much
more intact.
Conclusion
Regarding to immunosuppressive effects of opioids, evalu-
ation of enzyme activity studies was performed parallel to
structural changes caused by different concentrations of
test compounds. Thebaine activated ADA in certain low
concentrations; while in higher concentrations it inhibited
the enzyme. On the contrary, all other compounds inhib-
ited the enzyme in studied range (0-300 μM). The inter-
action site as well as existing interactions in stabilization
of each compound was obtained by docking studies. Fi-
nally, changes in two and three dimensional structures of
ADA (based on Circular dichroism and fluorescence spec-
troscopy Figure 3 and 4) revealed that only cocaine and
homatropine, had major effects on the enzyme (made
drastic changes in the enzyme); while these changes were
not significant for morphine, etylmorphine and thebaine
in studied concentrations.
Regarding that the adenosine deaminase enzyme has a
very important role in the immune system activity, so
the inhibition of this enzyme's natural function in the
human body can lead to debilitation of the immune sys-
tem. Therefore, the results of this experiment support
the idea that persons with addiction and regular drug
abuse have a weaker immune system than others. This
study can also help other researchers to develop a new
class of ADA activators or inhibitors in the near future
to manage malfunction of the immune system.
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